All News
Economic, Personal Burden of RA: Maybe Not So Bad?
d
MedPage Today
Data from a major federal survey indicate that people with rheumatoid arthritis (RA) don't pay massively more for healthcare than other folks, nor is their risk for functional deficits tremendously greater, researchers found.
Read Article
Barriers to Treat-to-Target in Rheumatoid Arthritis
A systematic and scoping literature examined the Treat-to-target (T2T) approach to rheumatoid arthritis (RA), noting its implementation is suboptimal and finding many barriers to implementation.
Read Article
Gout Forecast: 70% Increase by 2050
The Global Burden of Diseases, Injuries, and Risk Factors Study of 2021 has forecasted prevalence of gout to increase by 70% by 2050. In the USA, the prevalence of gout is estimated to be 10.3 million. As of 2020, 55.8 million people globally had gout, with a prevalence of 659.3 per 100 000 (this represents a 22.5% increase since 1990).
Read Article
CARRA Consensus Treatment for Refractory Juvenile Dermatomyositis
CARRA has developed consensus treatment plans for the use of biologic disease-modifying antirheumatic drugs (bDMARDs) in patients with refractory, moderately severe juvenile dermatomyositis. Juvenile dermatomyositis is the most common form of idiopathic, inflammatory myositis in childhood, with an estimated incidence of 3.2 per million children per year in the United States.
Read Article
FDA issued draft guidance, which, if implemented, would remove requirement for a switching study for demonstrating biosimilar interchangeability. Citing research showing no additional safety concerns if pts switched from reference biologics to biosimilars https://t.co/MBvI4yxajW https://t.co/sEE654E2rl
Dr. John Cush RheumNow ( View Tweet)
N Zealand Rheum Assn audit of 355 new seropositive pts referred, saw 65% starting DMARDs w/in 6 wks. DMARD starts were linked rurality & the # of rheumatologists. If there was 1 Rheum FTE/100,000 population, 80% were on DMARDs <=6wks https://t.co/8OvniRQt1I https://t.co/TsgegOJ9ZG
Dr. John Cush RheumNow ( View Tweet)
US News & World Report Top US Med Schools for Research
Baylor
Case Western
Emory
Hofstra
Mayo
Northwestern
Ohio State
UCLA
UCSD
UCSF
U Cincinnati
U Colorado
U Pittsburgh
UTSW
Vanderbilt
Yale
https://t.co/VSEnBxWUF2 https://t.co/bGCBCD8npX
Dr. John Cush RheumNow ( View Tweet)
Calif Cohort of 19340 rheumatic pts, finds Cardiovascular events (CVE) in 1.4% & antiphospholipid syndr in 5.5%. CVE increased risk of adverse pregnancy outcomes (>50%), including Sm for Gestational age (aRRs 1.2-1.5), Premature birth (aRR 1.6) https://t.co/9lxzrOVEks https://t.co/Jcm7tH61cv
Dr. John Cush RheumNow ( View Tweet)
Lit review of ILD in anti-synthetase syndrome finds no conclusive evidence of effective treatment. 10 studies, 514 pts (68% female); Hi Res CT positive in 87% w/ 49% having NSIP pattern. 48% Jo-1+, 28% Ro52+. Low improvements w/ RTX (12%), CYC (17%). https://t.co/oJ0EMAE7d0 https://t.co/bDiA1h9hO7
Dr. John Cush RheumNow ( View Tweet)
Systematic review: RX of macrophage activation syndr (MAS), included 57 reports, 1148 MAS pts (889 sJIA, 137 SLE). Most effective was high-dose GCs, IL-1 (83%) & IFNγ (93%) inhibitors, especially in sJIA-MAS. Also Ciclosporin, etoposide, Ruxolitinib https://t.co/4EnMOnlcYl https://t.co/PQnAZLvVwq
Dr. John Cush RheumNow ( View Tweet)
Full Read Overview of the safety of bDMARDs/tsDMARDS - contraindications, precautions, & boxed warnings for treatment of RA, PsA, SpA, JIA - safety checklist for a class of drugs you use and diseases you treat https://t.co/TIdCtJjF21 https://t.co/UE0nGbESDB
Links:
Dr. John Cush RheumNow ( View Tweet)
Study of 136 referred LBP pts (71 w/ DDD, 38 DISH, 27 axSpA) found significant overlap of imaging features in all 3. SpA-like spine CR features were found in 1/4 of patients with DISH, and MRI BM edema found in 1/3 of those patients. https://t.co/dKIcuE3IGZ https://t.co/OITtOKEuNC
Dr. John Cush RheumNow ( View Tweet)
Decline in Physician Trust During the COVID-19 Pandemic
AMA reports that following the COVID-19 pandemic US adults trust in physicians and hospitals decreased, and was associated with lower odds of COVID vaccination.
https://t.co/3XcMYcnzD3 https://t.co/yiIvOp1o5a
Dr. John Cush RheumNow ( View Tweet)
Frequency and Features of CPPD
An international cohort study of patients with CPPD disease identifies both acute and chronic inflammatory phenotypes, each with distinctive clinical and imaging diagnostic features.
https://t.co/3ox3YjVh5w https://t.co/1pB9f42a9M
Dr. John Cush RheumNow ( View Tweet)
Ischemic Forearm Exercise Testing is used to Dx McArdles disease & the absence of elevated blood lactate levels during exercise in pts w/ myophosphorylase deficiency (McArdle disease) https://t.co/pNxl6qnnIR https://t.co/kOyk45Necd
Dr. John Cush RheumNow ( View Tweet)
NEJM Case: A 29-year-old woman with SLE presented to the dermatology clinic with 2-weeks of itchy, painful rash on her nose and hands that came on with cold weather. What do you think? https://t.co/jm0Zzu1gfj https://t.co/sAgZipPmaC
Dr. John Cush RheumNow ( View Tweet)
Study of 201 pts w/ chronic pain, prevalence of anxiety was 19%; higher in women (OR 7.94) longer pain (OR:1.3) & severe pain(OR:18.7) https://t.co/LD6pjH25qv https://t.co/mrlEo0UkEw
Dr. John Cush RheumNow ( View Tweet)
2024 EULAR Points to consider when treating patients with cancer
https://t.co/oXO8m8mrfJ https://t.co/v69zPteDr0
Dr. John Cush RheumNow ( View Tweet)
Pain Reduction with Methotrexate in Knee Osteoarthritis
The Annals of Internal Medicine reports that oral, low dose, weekly methotrexate significantly reduced knee osteoarthritis (KOA) pain, stiffness, and function in a randomized controlled trial.
https://t.co/ayMD1V67fH https://t.co/Es3oPYM8Y3
Dr. John Cush RheumNow ( View Tweet)
Medical literature review of suggests low vitamin D status is common in Rheumatic pts. & low vit D levels linked to loss of muscle strength, MSK pain, sarcopenia & falls (esp in IIM, PMR, SLE, RA, SSc) (BUT DOES REPLACING VITAMIN D FIX THESE PROBLEMS???) https://t.co/30IiKj7l4d https://t.co/ydU6FQMTi5
Dr. John Cush RheumNow ( View Tweet)